Back to results
US 2025/0017933 A1Published application
Cancer treatment using lsd1 inhibitors and plk1 inhibitors
AssigneeCardiff Oncology, Inc.
InventorsMaya Ridinger, Anju Karki
Life of this patent
Estimating the term…
Abstract
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an LSD1 inhibitor and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit or reduce progression of the cancer.
Claims71
A method of treating cancer, the method comprising:
- administrating a lysine-specific histone demethylase 1 (LSD1) inhibitor and a Polo-like kinase 1 (PLK1) inhibitor to a subject with cancer, thereby inhibiting or reducing progression of the cancer in the subject.
A method of sensitizing cancer cells to a lysine-specific histone demethylase 1 (LSD1) inhibitor, the method comprising:
- contacting cancer cells with a composition comprising a Polo-like kinase 1 (PLK1) inhibitor, thereby sensitizing the cancer cells to the LSD1 inhibitor.
A kit, comprising:
- a Polo-like kinase 1 (PLK1) inhibitor;
- and
- a manual providing instructions for co-administrating the PLK1 inhibitor with a lysine-specific histone demethylase 1 (LSD1) inhibitor to a subject in need thereof for treating cancer.
Dependencies are inferred from the claim text.